Drugplain

Glimepiride 2 mg/1

Glimepiride · TABLET · Dr. Reddy's Laboratories Limited

10 Recalls on Record
Plain English

Glimepiride is a tablet containing glimepiride at 2 mg/1, taken oral. Manufactured by Dr. Reddy's Laboratories Limited.

Key Facts

Brand Name
Glimepiride
Generic Name
Glimepiride
NDC Code (Product)
55111-321
Manufacturer
Dr. Reddy's Laboratories Limited
Strength
2 mg/1
Dosage Form
TABLET
Route
ORAL
Marketing Status
Application #
ANDA077091
Drug Class
Sulfonylurea [EPC]
Marketing Start
10/06/2005

Recall History

10 Recalls on Record
Class II03/13/2023

Direct Rx

cGMP deviations

TerminatedVoluntary: Firm initiated
Class II03/23/2023

Preferred Pharmaceuticals, Inc.

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

OngoingVoluntary: Firm initiated
Class II03/17/2023

Amerisource Health Services LLC

CGMP Deviations: recalling drug products following an FDA inspection.

TerminatedVoluntary: Firm initiated
Class II02/10/2017

Sandoz Inc

Failed Dissolution Specifications

TerminatedVoluntary: Firm initiated
Class II04/06/2023

PD-Rx Pharmaceuticals, Inc.

CGMP deviations.

TerminatedVoluntary: Firm initiated
Class III01/18/2024

Dr. Reddy's Laboratories, Inc.

Misprint on tablet

OngoingVoluntary: Firm initiated
Class II02/07/2023

Accord Healthcare, Inc.

CGMP Deviations: recalling drug products following an FDA inspection.

TerminatedVoluntary: Firm initiated
Class II03/13/2023

Direct Rx

cGMP deviations

TerminatedVoluntary: Firm initiated
Class II03/16/2023

Northwind Pharmaceuticals LLC

CGMP Deviations

OngoingVoluntary: Firm initiated
Class II03/13/2023

Direct Rx

cGMP deviations

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

blood glucose increased2,987 reports
nausea2,305 reports
diarrhoea2,221 reports
drug ineffective1,928 reports
fatigue1,849 reports
hypoglycaemia1,661 reports
weight decreased1,403 reports
dizziness1,376 reports
dyspnoea1,334 reports
vomiting1,321 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. Glimepiride tablets are a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 ). Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis ( 1 ).

Dosage & Administration

2 DOSAGE AND ADMINISTRATION Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily ( 2.1 ). Administer with breakfast or first meal of the day ( 2.1 ). Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment) ( 2.1 ). 2.1 Recommended Dosing Glimepiride tablets should be administered with breakfast or the first main meal of the day. The recommended starting dose of glimepiride tablets are 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5 , 8.6) ]. After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient’s glycemic response. Uptitration should not occur more frequently than every 1 to 2 weeks. A conservative titration scheme is recommended for patients at increased risk for hypoglycemia [see Warnings and Precautions (

Contraindications

4 CONTRAINDICATIONS Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: Glimepiride or any of the product’s ingredients [see Warnings and Precautions (5.2) ]. Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. Do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives. Hypersensitivity to glimepiride or any of the product’s ingredients ( 4 ) Hypersensitivity to sulfonamide derivatives ( 4 )

Drug Interactions

7 DRUG INTERACTIONS Certain medications may affect glucose metabolism, requiring glimepiride tablets dose adjustment and close monitoring of blood glucose ( 7.1 ). Miconazole: Severe hypoglycemia can occur when glimepiride and oral miconazole are used concomitantly. ( 7.2 ). Cytochrome P450 2C9 interactions: Inhibitors and inducers of cytochrome P450 2C9 may affect glycemic control by altering glimepiride plasma concentrations ( 7.3 ). Colesevelam: Coadministration may reduce glimepiride absorption. Glimepiride should be administered at least 4 hours prior to colesevelam ( 2.1 , 7.4 ). 7.1 Drugs Affecting Glucose Metabolism A number of medications affect glucose metabolism and may require glimepiride tablets dose adjustment and particularly close monitoring for hypoglycemia or worsening glycemic control. The following are examples of medications that may increase the glucose-lowering effect of sulfonylureas including glimepiride, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin

Adverse Reactions

6 ADVERSE REACTIONS The following serious adverse reactions are discussed in more detail below and elsewhere in the labeling: Hypoglycemia [see Warnings and Precautions (5.1) ] Hemolytic anemia [see Warnings and Precautions (5.3) ] In clinical trials, the most common adverse reactions with glimepiride were hypoglycemia, dizziness, asthenia, headache, and nausea. Common adverse reactions in clinical trials (≥5% and more common than with placebo) include hypoglycemia, headache, nausea, and dizziness ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories, Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Approximately 2,800 patients with type 2 diabetes have been treated with glimepiride in the controlled clinical trials. In these trials, approximately 1,700 patients were treated with glimepiride for at least 1 year. Table 1 summarizes adverse ev

Frequently Asked Questions

What is Glimepiride used for?

Glimepiride contains Glimepiride. It is a tablet taken oral. Consult your doctor for specific uses.

Is Glimepiride a controlled substance?

Glimepiride is not classified as a controlled substance by the DEA.

What is the generic name for Glimepiride?

The generic name for Glimepiride is Glimepiride. There are no other listed brand versions of Glimepiride.

What is the NDC code for Glimepiride 2 mg/1?

The NDC (National Drug Code) for Glimepiride 2 mg/1 is 55111-321, listed by Dr. Reddy's Laboratories Limited.

Product NDC

55111-321

Package NDC

55111-321-01

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)